Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy

Area of Science:

• Hepatology
• Neurology
• Gastroenterology

Background:

• Minimal hepatic encephalopathy (mHE) is a frequent complication in cirrhotic liver disease patients, contributing to significant morbidity and mortality.
• mHE often manifests subtly with cognitive impairment and behavioral changes, complicating diagnosis.
• A history of falls or accidents can be indicative of undiagnosed mHE.

Purpose of the Study:

• To review the diagnostic challenges and therapeutic strategies for minimal hepatic encephalopathy (mHE) in cirrhotic liver disease.
• To emphasize the importance of early detection and management of mHE to prevent progression to overt hepatic encephalopathy.
• To discuss current and emerging treatments aimed at reducing ammonia levels.

Main Methods:

• Diagnosis relies on psychometric testing, notably the psychometric hepatic encephalopathy score (PHES), often in conjunction with electroencephalograms.
• Biochemical markers currently lack a role in diagnosing mHE.
• Treatment decisions are guided by symptom severity, focusing on ammonia-lowering therapies after addressing other comorbidities.

Main Results:

• Psychometric tests, particularly PHES, are essential for mHE diagnosis.
• Laxatives and rifaximin are primary treatments, reducing ammonia absorption.
• Other therapies like BCAA, LOLA, L-carnitine, and phenylbutyrate modulate ammonia metabolism and excretion.
• Shunt reduction may be necessary for mHE related to portosystemic shunts.

Conclusions:

• Early identification and management of mHE are vital for improving patient outcomes and preventing severe cognitive decline.
• Ammonia-lowering therapies are the cornerstone of mHE treatment.
• Further research into novel therapeutic targets for mHE is warranted.